Review



hmec basal media  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    ATCC hmec basal media
    Hmec Basal Media, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 305 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hmec+medium/Mammary+Epithelial+Cell+Basal+Medium/pm41893940-41-4-7
    Average 99 stars, based on 305 article reviews
    hmec basal media - by Bioz Stars, 2026-11
    99/100 stars

    Images

    Related Articles

    Cell Culture:

    Article Title: Thymoquinone decreases cell proliferation and immune evasion of breast cancer cells by reducing CD55 and CD114 levels.
    Article Snippet: Cell proliferation has emerged as a distinctive key feature needed for tumor development [1].. The continuous growth of tumor cells involves altered proliferation of the cell, one of the hallmarks of cancer [2].. Proliferation of cancer cells is mediated by aberrant expression of growth-related proteins, the membranebound receptors [3].

    Article Title: Extracellular vesicle-induced silver-nanoparticle aggregation (EVISA) assay for rapid measurement of EV concentration.
    Article Snippet: a non-invasive approach for assessing disease progression, monitoring therapeutic responses, and enabling early diagnosis [3, 10–15].. Some studies have explored EV cargo for early cancer detection, such as lung, breast, pancreatic, and gastric cancer, uncovering upregulated proteomic and/or genomic markers for early cancer detection and predictors of disease progression [16–23].. However, not only can the molecular cargo predict disease, but also the quantity of EVs tend to increase during disease, as seen in cardiovascular disease, liver disorders, and cancer [24–27].

    Article Title: Polymerase iota coordinates adaptation to replication stress in BRCA2-deficient mammary epithelial cells.
    Article Snippet: MCF7 and HeLa were maintained in DMEM medium (ThermoFisher Scientific,11965092) supplemented with 10% fetal bovine serum (ThermoFisher Scientific, A5256701) and penicillin-streptomycin. .. Commercially available primary HMECs were cultured in Mammary Epithelial Cell Basal Medium supplemented with the Mammary Epithelial Cell Growth Kit according to the manufacturer’s instructions (ATCC, PCS-600–010, PCS-600–030, PCS-600–040). ..

    other:

    Article Title: Autophagy-lysosomal dependency defines a vulnerable physiological state in drug-tolerant persister cells of triple-negative breast cancer.
    Article Snippet: 1 Department of Biological Sciences, National Institute of Pharmaceutical Education and Research, Balanagar, Hyderabad 500037, India 2 Dept.. of Biotechnology and Bioinformatics, Sambalpur University, Jyoti Vihar, Burla, Odisha 768019, India 3 Department of Animal Biology, School of Life Sciences, University of Hyderabad, Hyderabad 500046, India 4 Council of Scientific and Industrial Research (CSIR)-Centre for Cellular and Molecular Biology, Hyderabad 500007, India Abstract Triple-negative breast cancer (TNBC), a subtype of aggressive breast cancer, has limited treatment options.. Recurrent disease caused by drug-tolerant persister cells (DTPs) that evade chemotherapeutic agents (e.g., doxorubicin hydrochloride (DOX) and paclitaxel (PTX)) is a significant challenge in treating TNBC.

    Multiple Displacement Amplification:

    Article Title: Assessment of the anticancer and antimetastatic effects of monocarbonyl analogs of curcumin, C66 and B2BrBC, in breast cancer cells
    Article Snippet: Breast cancer (MCF-7, MDA-MB-231, and BT-474) and non-carcinogenic breast epithelial (MCF-10 A) cells were purchased from the American Type Culture Collection (ATCC) (Cat. # HTB-22, HTB-26, HTB-20, and CRL-10317, respectively). .. MCF-7 and MDA-MB-231 cells were grown in DMEM/F12 (50:50) medium (Corning, Cat. # 10–092-CM), BT-474 cells in RPMI1-1640 medium (ATCC, Cat. # 30–2001), and MCF-10 A cells in Mammary Epithelial Cell Basal medium (ATCC, Cat. # PCS-600-030) supplemented with Mammary Epithelial Cell Growth kit (ATCC, Cat. # PCS-600-040), 10% FBS (Avantor, Cat. # 89510-186) and antibiotic/antimycotic solution (Corning, Cat. # 30-004-Cl) and incubated at 37 °C and 5% CO 2 . ..

    Incubation:

    Article Title: Assessment of the anticancer and antimetastatic effects of monocarbonyl analogs of curcumin, C66 and B2BrBC, in breast cancer cells
    Article Snippet: Breast cancer (MCF-7, MDA-MB-231, and BT-474) and non-carcinogenic breast epithelial (MCF-10 A) cells were purchased from the American Type Culture Collection (ATCC) (Cat. # HTB-22, HTB-26, HTB-20, and CRL-10317, respectively). .. MCF-7 and MDA-MB-231 cells were grown in DMEM/F12 (50:50) medium (Corning, Cat. # 10–092-CM), BT-474 cells in RPMI1-1640 medium (ATCC, Cat. # 30–2001), and MCF-10 A cells in Mammary Epithelial Cell Basal medium (ATCC, Cat. # PCS-600-030) supplemented with Mammary Epithelial Cell Growth kit (ATCC, Cat. # PCS-600-040), 10% FBS (Avantor, Cat. # 89510-186) and antibiotic/antimycotic solution (Corning, Cat. # 30-004-Cl) and incubated at 37 °C and 5% CO 2 . ..



    Similar Products

    99
    ATCC hmec basal media
    Hmec Basal Media, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hmec+medium/Mammary+Epithelial+Cell+Basal+Medium/pm41893940-41-4-7
    Average 99 stars, based on 1 article reviews
    hmec basal media - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    86
    Procell Inc hmec 1 cell complete medium
    Hmec 1 Cell Complete Medium, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hmec+medium/culture+huvecs+medium/pm41581639-57-9-13
    Average 86 stars, based on 1 article reviews
    hmec 1 cell complete medium - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    96
    ATCC hmec 1 cells
    Hmec 1 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hmec+medium/F-12K+Medium/us12473367-1054-0-3
    Average 96 stars, based on 1 article reviews
    hmec 1 cells - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    95
    PromoCell hmec 1 cells
    Hmec 1 Cells, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hmec+medium/Endothelial+Cell+Basal+Medium/10__1016_slash_j__cellsig__2025__112091-222-0-20
    Average 95 stars, based on 1 article reviews
    hmec 1 cells - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    97
    ATCC 131 medium
    131 Medium, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hmec+medium/HMEC-1/pm40565011-239-10-5
    Average 97 stars, based on 1 article reviews
    131 medium - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    90
    Lonza hmec medium
    Net gain aneuploidy is associated with metabolic phenotypes and is prognostic for response to DNA-damaging chemotherapy in cancer. ( A ) Volcano plot <t>showing</t> <t>metabolite</t> log 2 fold change (log 2 FC) ( X -axis) and −log 10 ( P -value) ( Y -axis) in net gain aneuploid HMECs compared with diploid <t>HMEC</t> controls under steady-state conditions. Log 2 FC capped at minimum −3 and maximum 3. ( B ) Volcano plot showing linear regression coefficient ( X -axis) and corresponding −log 10 ( P -value) ( Y -axis) of metabolite levels compared with net gain aneuploidy levels across cancer cell lines. ( C ) Volcano plot showing linear regression coefficient ( X -axis) and corresponding −log 10 ( P -value) ( Y -axis) of metabolite levels compared with net gain aneuploidy levels across a cohort of human breast cancer samples (aneuploidy levels inferred from matched RNA-seq data). ( D ) Heat map of differentially essential gene sets associated with net gain aneuploidy across DepMap cancer cell line CRISPR screen data ( right column) showing a pattern similar to that of the aneuploidy epistasis profile of HMECs ( left column). Gene set enrichment analysis (KEGG gene sets) was performed on a gene list ranked by the correlation of effect scores with net gain aneuploidy levels. HMEC data are summarized from CRISPR screens in . ( E ) Gene effect scores of mitochondrially localized genes are mostly negatively correlated with net gain aneuploidy levels across cancer cell lines. ( F ) Gene set enrichment plots showing all mitochondrially localized genes ( top ) or just oxidative phosphorylation genes ( bottom ) using the gene ranking in D . ( G ) Overall survival across a 5 year time frame of breast cancer patients from the TCGA cohort with aneuploid tumors classified as either “net gain” or “net loss,” treated with DNA-damaging/antinucleotide/antimetabolite chemotherapeutics ( left panel) or without chemotherapy ( right panel). Hazard ratios and associated P -values were calculated from Cox proportional hazards regression models. ( H ) Diagram depicting a net gain aneuploidy nucleotide insufficiency model and putative therapeutic vulnerability. Increased nucleotide pool requirements render net gain aneuploid cells sensitive to nucleotide pool stress caused by nucleotide synthesis inhibitors or DNA damage. This nucleotide pool stress cannot be fully rescued by uridine salvage and results in p53 activation and cell cycle arrest, whereas diploid cells can replicate efficiently using salvage alone.
    Hmec Medium, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hmec+medium/hmec+medium/pmc12128873-176-11-11
    Average 90 stars, based on 1 article reviews
    hmec medium - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results


    Net gain aneuploidy is associated with metabolic phenotypes and is prognostic for response to DNA-damaging chemotherapy in cancer. ( A ) Volcano plot showing metabolite log 2 fold change (log 2 FC) ( X -axis) and −log 10 ( P -value) ( Y -axis) in net gain aneuploid HMECs compared with diploid HMEC controls under steady-state conditions. Log 2 FC capped at minimum −3 and maximum 3. ( B ) Volcano plot showing linear regression coefficient ( X -axis) and corresponding −log 10 ( P -value) ( Y -axis) of metabolite levels compared with net gain aneuploidy levels across cancer cell lines. ( C ) Volcano plot showing linear regression coefficient ( X -axis) and corresponding −log 10 ( P -value) ( Y -axis) of metabolite levels compared with net gain aneuploidy levels across a cohort of human breast cancer samples (aneuploidy levels inferred from matched RNA-seq data). ( D ) Heat map of differentially essential gene sets associated with net gain aneuploidy across DepMap cancer cell line CRISPR screen data ( right column) showing a pattern similar to that of the aneuploidy epistasis profile of HMECs ( left column). Gene set enrichment analysis (KEGG gene sets) was performed on a gene list ranked by the correlation of effect scores with net gain aneuploidy levels. HMEC data are summarized from CRISPR screens in . ( E ) Gene effect scores of mitochondrially localized genes are mostly negatively correlated with net gain aneuploidy levels across cancer cell lines. ( F ) Gene set enrichment plots showing all mitochondrially localized genes ( top ) or just oxidative phosphorylation genes ( bottom ) using the gene ranking in D . ( G ) Overall survival across a 5 year time frame of breast cancer patients from the TCGA cohort with aneuploid tumors classified as either “net gain” or “net loss,” treated with DNA-damaging/antinucleotide/antimetabolite chemotherapeutics ( left panel) or without chemotherapy ( right panel). Hazard ratios and associated P -values were calculated from Cox proportional hazards regression models. ( H ) Diagram depicting a net gain aneuploidy nucleotide insufficiency model and putative therapeutic vulnerability. Increased nucleotide pool requirements render net gain aneuploid cells sensitive to nucleotide pool stress caused by nucleotide synthesis inhibitors or DNA damage. This nucleotide pool stress cannot be fully rescued by uridine salvage and results in p53 activation and cell cycle arrest, whereas diploid cells can replicate efficiently using salvage alone.

    Journal: Genes & Development

    Article Title: Aneuploidy generates enhanced nucleotide dependency and sensitivity to metabolic perturbation

    doi: 10.1101/gad.352512.124

    Figure Lengend Snippet: Net gain aneuploidy is associated with metabolic phenotypes and is prognostic for response to DNA-damaging chemotherapy in cancer. ( A ) Volcano plot showing metabolite log 2 fold change (log 2 FC) ( X -axis) and −log 10 ( P -value) ( Y -axis) in net gain aneuploid HMECs compared with diploid HMEC controls under steady-state conditions. Log 2 FC capped at minimum −3 and maximum 3. ( B ) Volcano plot showing linear regression coefficient ( X -axis) and corresponding −log 10 ( P -value) ( Y -axis) of metabolite levels compared with net gain aneuploidy levels across cancer cell lines. ( C ) Volcano plot showing linear regression coefficient ( X -axis) and corresponding −log 10 ( P -value) ( Y -axis) of metabolite levels compared with net gain aneuploidy levels across a cohort of human breast cancer samples (aneuploidy levels inferred from matched RNA-seq data). ( D ) Heat map of differentially essential gene sets associated with net gain aneuploidy across DepMap cancer cell line CRISPR screen data ( right column) showing a pattern similar to that of the aneuploidy epistasis profile of HMECs ( left column). Gene set enrichment analysis (KEGG gene sets) was performed on a gene list ranked by the correlation of effect scores with net gain aneuploidy levels. HMEC data are summarized from CRISPR screens in . ( E ) Gene effect scores of mitochondrially localized genes are mostly negatively correlated with net gain aneuploidy levels across cancer cell lines. ( F ) Gene set enrichment plots showing all mitochondrially localized genes ( top ) or just oxidative phosphorylation genes ( bottom ) using the gene ranking in D . ( G ) Overall survival across a 5 year time frame of breast cancer patients from the TCGA cohort with aneuploid tumors classified as either “net gain” or “net loss,” treated with DNA-damaging/antinucleotide/antimetabolite chemotherapeutics ( left panel) or without chemotherapy ( right panel). Hazard ratios and associated P -values were calculated from Cox proportional hazards regression models. ( H ) Diagram depicting a net gain aneuploidy nucleotide insufficiency model and putative therapeutic vulnerability. Increased nucleotide pool requirements render net gain aneuploid cells sensitive to nucleotide pool stress caused by nucleotide synthesis inhibitors or DNA damage. This nucleotide pool stress cannot be fully rescued by uridine salvage and results in p53 activation and cell cycle arrest, whereas diploid cells can replicate efficiently using salvage alone.

    Article Snippet: Six hours prior to metabolite isolation, the cells were treated with Lonza HMEC medium containing 10 mM 13 C 4 -aspartate (Sigma), and the pH was adjusted to 7.4 with the relevant treatments.

    Techniques: RNA Sequencing, CRISPR, Phospho-proteomics, Activation Assay